Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: growthvalue who wrote (24462)	8/13/1998 3:22:00 PM
From: Machaon	Respond to of 32384

GV: Your response would be a good note for SI to highlight, not necessarily about LGND, but about biotechs in general. Obviously, you have a lot more experience with biotechs, than I have. Thanks for your in-depth evaluation. I'm sure that most of the readers on this thread appreciate the "breath of fresh air"! I need to pay more attention to work right now, so I'll still have the funds to invest in the market. Thanks for the note, Bob

To: growthvalue who wrote (24462)	8/13/1998 4:37:00 PM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 32384

>I'm saying I think the acquisition probably added a little value to >the company (which is why I HOPE they did it) but that the overall >effect was pretty insignificant. It's kind of strange that LGND put in what appears to be a major effort just to add a little value to the company. I still think there has to be more to it. Cheers, Torben

To: growthvalue who wrote (24462)	8/13/1998 6:02:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< "My guess is that they wanted to effect revenues and earnings ASAP, and ONTAK would do this for them.">> ===> I hope that's not the reason! What's the point of effecting accounting earnings and revenue if it doesn't add value to the company? Putting aside the argument over whether Seragen adds value, or not.... The market is revenue hungry, at this time. The biotech industry is suffering major harm right now. New biotech IPOs are being shelved due to lack of funding and market interest. Ligand should understand this. Most biotechs KNOW, in present market conditions, that the sooner they take in bucks, the sooner the market will reward them. (with a few exceptions such as ENMD.) As an investor in LGND, I appreciate their pipeline, but I am also very interested in Ligand's move to profitability. Good conversations today on the LGND thread, both Pro and Con. Too bad it's got to end soon. Regards, Bob